IBI-322
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for IBI-322, covering 2024-01-10 to 2024-01-10. Get the full timeline:
Most recent: Clinical Trial Update: Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer [Phase 2]